Research progress of tumor abnormal proteins in gastrointestinal malignancies

doi:10.3877/cma.j.issn.1674-0793.2025.05.014

Abstract

Abstract:

Tumor abnormal proteins (TAP) are formed due to abnormal glycosylation when human cells become malignant, and are eventually released into blood. Researches of TAP in gastrointestinal tumors have been extensively conducted, with the results indicating a high expression in many malignant tumors. This article discusses the research progress of digestive tract tumors in combination with domestic and foreign literature, providing references for clinical work.

Key words: Tumor abnormal proteins, Malignant tumors, Tumor biomarkers

Xiaoxin Duan, Sizhuo Wang, Long Chen, Shengli Dong. Research progress of tumor abnormal proteins in gastrointestinal malignancies[J]. Chinese Archives of General Surgery(Electronic Edition), 2025, 19(05): 356-360.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhptwkxwx.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-0793.2025.05.014

https://zhptwkxwx.cma-cmc.com.cn/EN/Y2025/V19/I05/356

References 30

［1］	刘宗超, 李哲轩, 张阳, 等. 2020全球癌症统计报告解读[J/OL]. 肿瘤综合治疗电子杂志, 2021, 7(2): 1-14.
［2］	Han B, Zheng R, Zeng H, et al. Cancer incidence and mortality in China, 2022[J]. J Natl Cancer Cent, 2024, 4(1): 47-53.
［3］	Wang C, Gu Y, Men X, et al. TAP test image dynamic tracking study after thyroid cancer surgery and after radiotherapy and chemotherapy[J]. Comput Math Methods Med, 2021, 2021: 8072126.
［4］	Song H, Zhang M, Guo C, et al. Implication of protein post translational modifications in gastric cancer[J]. Front Cell Dev Biol, 2025, 13: 1523958.
［5］	Arora K, Sherilraj PM, Abutwaibe KA, et al. Exploring glycans as vital biological macromolecules: A comprehensive review of advancements in biomedical frontiers[J]. Int J Biol Macromol, 2024, 268(Pt 1): 131511.
［6］	Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249.
［7］	Chen W, Li D, Bian X, et al. Peripheral blood markers predictive of progression-free survival in advanced esophageal squamous cell carcinoma patients treated with PD-1 inhibitors plus chemotherapy as first-line therapy[J]. Nutr Cancer, 2023, 75(1): 207-218.
［8］	Cheng Y, Fang Q, Chen Y, et al. High expression of tumor abnormal protein preoperatively predicts poor prognosis of patients with esophageal squamous cell carcinoma[J]. Front Surg, 2021, 8: 609719.
［9］	肖中岳, 轩青霞, 袁小志. TAP检测联合增强CT对食管癌术前淋巴结转移评估的临床意义[J]. 食管疾病, 2021, 3(2): 102-105.
［10］	张喆, 汪阔. 肿瘤标志物TAP、CEA、CA19–9检测在食管癌诊断中的应用价值[J]. 检验医学与临床, 2022, 19(3): 313-315, 320.
［11］	Wang FH, Zhang XT, Li YF, et al. The Chinese Society of Clinical Oncology (CSCO): clinical guidelines for the diagnosis and treatment of gastric cancer, 2021[J]. Cancer Commun, 2021, 41(8): 747-795.
［12］	Gu C, Xie L, Li B, et al. Quantification of tumor abnormal proteins in the diagnosis and postoperative prognostic evaluation of gastric cancer[J]. Clin Med Insights Oncol, 2022, 16: 1-14.
［13］	Zhang M, Wang X, Wang Z. Early study of tumor abnormal protein in gastric adenocarcinoma[J]. Onco Targets Ther, 2021, 14: 1719-1726.
［14］	黄慧, 谭玲霞, 徐诗文, 等. 异常糖链糖蛋白及CA199与早期胃癌及癌前病变的相关性[J]. 中国现代医生, 2022, 60(6): 1-4.
［15］	Li Q, Ding C, Cao M, et al. Global epidemiology of liver cancer 2022: An emphasis on geographic disparities[J]. Chin Med J, 2024, 137(19): 2334-2342.
［16］	黄娜娜, 顾康生, 张逸寅, 等. 异常糖链糖蛋白在胆道良恶性肿瘤鉴别诊断中的价值[J]. 疑难病杂志, 2020, 19(12): 1233-1237.
［17］	Cai H, Li W, Zhang Y, et al. Preoperative tumor abnormal protein is a promising biomarker for predicting hepatocellular carcinoma oncological outcome following curative resection[J]. J Cancer Res Ther, 2022, 18(7): 2021-2026.
［18］	赵佳, 白云, 姜小建, 等. 肝特异性对比剂MR扫描联合异常糖链糖蛋白、甲胎蛋白、甲胎蛋白异质体L3检测在乙肝相关性肝细胞癌诊断中的应用价值[J]. 临床医学研究与实践, 2024, 9(3): 105-108, 129.
［19］	吴昊程, 张国坤, 赵双强, 等. 肿瘤异常糖蛋白联合传统肿瘤标志物对胆道恶性肿瘤早期诊断的价值[J]. 湖南师范大学学报(医学版), 2022, 19(2): 74-77.
［20］	游晓燕, 黄梨华, 邹春生. 血清PIVKA-Ⅱ、TAP、AFU联合检测在原发性肝癌早期诊断中的临床应用研究[J]. 现代诊断与治疗, 2023, 34(16): 2440-2442.
［21］	Stoffel EM, Brand RE, Goggins M. Pancreatic cancer: changing epidemiology and new approaches to risk assessment, early detection, and prevention[J]. Gastroenterology, 2023, 164(5): 752-765.
［22］	Levink IJM, Klatte DCF, Hanna-Sawires RG, et al. Longitudinal changes of serum protein N-Glycan levels for earlier detection of pancreatic cancer in high-risk individuals[J]. Pancreatology, 2022, 22(4): 497-506.
［23］	徐士其. TAP联合CA19–9对胰腺癌诊断价值的研究[D]. 大连: 大连医科大学, 2021.
［24］	赵瑞敏, 王小月, 张惠霞. 血清CA19–9、TAP、IgG4联合检测在IgG4相关性自身免疫性胰腺炎与胰腺癌鉴别诊断中的临床价值分析[J]. 肿瘤基础与临床, 2022, 35(2): 136-140.
［25］	柴玲姗, 李娅, 徐峰. 糖类抗原19–9、肿瘤异常蛋白和D-二聚体在胰腺癌诊断中的价值[J]. 肿瘤基础与临床, 2020, 33(1): 27-29.
［26］	Xi Y, Xu P. Global colorectal cancer burden in 2020 and projections to 2040[J]. Transl Oncol, 2021, 14(10): 101174.
［27］	Morgan E, Arnold M, Gini A, et al. Global burden of colorectal cancer in 2020 and 2040: incidence and mortality estimates from globocan[J]. Gut, 2023, 72(2): 338-344.
［28］	闵曙光, 吴岳, 赵璐, 等. 结直肠癌中肿瘤异常糖蛋白检测的诊断效能评估[J]. 中国实验诊断学, 2023, 27(5): 557-561.
［29］	袁仁顺, 施海华. 肿瘤异常糖链糖蛋白在结直肠癌诊断中的应用价值[J]. 中国临床研究, 2022, 35(6): 797-800.
［30］	刘行, 牛跃平, 董峰, 等. 血清VEGF结合TAP在贝伐珠单抗联合化疗治疗转移性结直肠癌中疗效的评价[J]. 智慧健康, 2021, 7(14): 120-123.

[1]	Qiu-yu HUANG, Xing-fang HE, Dong-ye YANG, Hai-chao LIU, Hua WANG. The nursing care of immune cell therapy on malignant tumors in oral and maxillofacial region [J]. Chinese Journal of Stomatological Research(Electronic Edition), 2012, 6(05): 453-456.
[2]	Huayue Yan, Zixiang Liu, Shaobo Zhou. Research progress of phosphoenolpyruvate carboxykinase-1 in malignant tumors [J]. Chinese Archives of General Surgery(Electronic Edition), 2024, 18(06): 452-456.
[3]	Cong Zhang, Cheng Li. Research progress on the prognosis status and related factors of surgical treatment for malignant tumors in the pancreatic head region [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2025, 19(05): 574-578.
[4]	Shan Wang, Qing Ma, Lan Yao, Huayu Yang. Correlation between folic acid therapy and serum level of miR-150-5p in elderly patients undergoing maintenance hemodialysis [J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2023, 12(03): 139-144.
[5]	Chenchen Song, Tianci Liang, Yue Zhao, Chaoyi Zhang, Hui Wang, Tingzhi Wen, Biaoxue Rong. Advances in research of collagen type X alpha 1 in malignant tumors [J]. Chinese Journal of Clinicians(Electronic Edition), 2025, 19(03): 221-228.
[6]	Yihan Wu, Zhang Lei, Hongda Lu. Progress in understanding of role of MUC16/CA125 in diagnosis and treatment of benign and malignant tumors [J]. Chinese Journal of Clinicians(Electronic Edition), 2023, 17(05): 591-595.
[7]	Yafei Wang, Zhenbiao Wu. Application of autoantibodies in management of dermatomyositis patients [J]. Chinese Journal of Clinicians(Electronic Edition), 2022, 16(08): 796-800.
[8]	Xueli Jiang, Hui Li, Jingjing Liu, Linna Zhang, Wenxiu Li, Jie Yao, Ying Cheng. Construction and application of biobank information database for malignant tumors [J]. Chinese Journal of Clinical Laboratory Management(Electronic Edition), 2019, 07(03): 184-189.

Please choose a citation manager

Content to export